Skip to contentpdufa.bio

SL-325 (DR3 antagonist antibody)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

SL-325 (DR3 antagonist antibody) is a Shattuck Labs, Inc. program in crohn's disease. Its next catalyst is a Readout in Q2 2028.

STTK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: Crohn's disease; Hidradenitis suppurativa. Sponsor: Shattuck Labs, Inc. (STTK). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2028STTKReadout · Q2 2028STTK

Specialist biotech funds holding STTK, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors6,306,127$43.0 millionfiled November 16, 2026
Redmile Group5,086,990$34.7 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is SL-325 (DR3 antagonist antibody)'s next FDA decision or readout?

The next tracked catalyst for SL-325 (DR3 antagonist antibody) is a Readout in Q2 2028.

What happened at SL-325 (DR3 antagonist antibody)'s most recent FDA decision?

No FDA decision for SL-325 (DR3 antagonist antibody) is in our archive yet.

What is SL-325 (DR3 antagonist antibody) used for?

In our records SL-325 (DR3 antagonist antibody) is under review or in development for Crohn's disease; Hidradenitis suppurativa.

Who makes SL-325 (DR3 antagonist antibody)?

Shattuck Labs, Inc. (STTK).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.